These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11962119)

  • 21. Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies.
    Minen MT; Lindberg K; Langford A; Loder E
    Headache; 2017 Sep; 57(8):1243-1251. PubMed ID: 28691382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expensive drugs and intergenerational justice].
    Hughes D
    Can J Public Health; 2010; 101(3):193-5. PubMed ID: 20737807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Regulators in access to anticancer drugs in Canada].
    Côté A; Keating B; Parent M; Simard G
    Sante Publique; 2015; 27(4):515-27. PubMed ID: 26751926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Income class and pharmaceutical expenditure in Canada: 1964-1990.
    Lexchin J
    Can J Public Health; 1996; 87(1):46-50. PubMed ID: 8991744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 31. National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities.
    Yoongthong W; Hu S; Whitty JA; Wibulpolprasert S; Sukantho K; Thienthawee W; Han H; Scuffham PA
    Value Health; 2012; 15(1 Suppl):S126-31. PubMed ID: 22265059
    [No Abstract]   [Full Text] [Related]  

  • 32. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waiting for reimbursement of new medicines in Canada: it's time for a rethink.
    Skinner BJ
    Pharmacoeconomics; 2008; 26(8):629-32. PubMed ID: 18620457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing psychotropic drug costs: will formularies work?
    Huskamp HA
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand.
    Rawson NSB
    Front Public Health; 2020; 8():544835. PubMed ID: 33194946
    [No Abstract]   [Full Text] [Related]  

  • 37. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    BMC Health Serv Res; 2013 Jan; 13():34. PubMed ID: 23363626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals.
    Schweitzer SO; Shiota SR
    Annu Rev Public Health; 1992; 13():399-410. PubMed ID: 1599596
    [No Abstract]   [Full Text] [Related]  

  • 39. A bitter pill: formulary variability and the challenge to prescribing physicians.
    Shrank WH; Ettner SL; Glassman P; Asch SM
    J Am Board Fam Pract; 2004; 17(6):401-7. PubMed ID: 15575031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Canadian health care system: an overview.
    Vayda E; Deber RB
    Soc Sci Med; 1984; 18(3):191-7. PubMed ID: 6422558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.